Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation

Ying Han1†, Ling Hou2†, Bowen Zhao1, Li Gao3 and Shiyan Li1*

1 Department of Ultrasound, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2 National Clinical Research Center for Child Health, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 3 Department of Head and Neck Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background: The BRAF V600E mutation is the most common genetic variant in papillary thyroid cancer (PTC), but the relationship between the BRAF V600E mutation in PTC and cervical lymph node metastasis (LNM) remains controversial.

Objective: To estimate risk factors for neck nodal metastasis in PTC with BRAF V600E mutation.

Patients: A total of 292 patients diagnosed with BRAF V600E mutation related PTC were admitted.

Design: In this retrospective study, data from 292 patients, including clinical, molecular, and ultrasonic characteristics, were analyzed. Univariate and multivariate logistic regression analyses were applied to identify risk factors for LNM in PTC with the BRAF V600E mutation.

Results: In the univariate analysis of all PTC patients with the BRAF V600E mutation, the LNM was found to be significantly associated with age ($P = 0.010$), size ($P = 0.000$), bilaterality ($P = 0.000$), multifocality ($P = 0.002$), LNM in ultrasound (US) ($P = 0.000$), and capsular invasion ($P = 0.010$). In ultrasonic image characteristics, margin ($P = 0.036$), shape ($P = 0.046$), and microcalcification ($P = 0.002$) were significantly associated with LNM. In multivariate analysis, LNM in PTCs with BRAF V600E mutation was significantly associated with age $\leq 45$ years (OR = 1.869, $P = 0.020$, 95% CI = 1.106 - 3.158), size $\geq 1$cm (OR = 3.131, $P = 0.001$, 95% CI = 1.578 - 6.212), LNM in ultrasound (US) (OR = 6.962, $P = 0.000$, 95% CI = 2.924 - 16.572), bilaterality (OR = 1.626, $P = 0.007$, 95% CI = 1.142 - 2.314), ill-defined margins in US (OR = 1.980, $P = 0.033$, 95% CI = 1.057 - 3.709), and microcalcification in US (OR = 2.786, $P = 0.002$, 95% CI = 1.464 - 5.303).

Conclusion: This study revealed that several significant risk factors for LNM in PTCs with the BRAF V600E mutation included: age $\leq 45$ years, size $\geq 1$cm, LNM in US, bilaterality, ill-defined margins in US, and microcalcification in US.

Keywords: BRAF V600E, thyroid carcinomas, lymph node, metastasis, multivariate analysis, risk factors
INTRODUCTION

Over the last decades, thyroid cancer has been one of the fastest growing and most prevalent endocrine malignancies worldwide (1, 2). It is 2.9 times more common in women than in men, possibly due to reproductive and hormonal factors (2). Papillary thyroid carcinoma (PTC) accounts for approximately 85% of thyroid cancers, as the most common differentiated thyroid carcinomas (DTC) with a favorable prognosis (3). In recent years, molecular markers have gained extensive attention to improving risk stratification of PTC (4).

In PTCs, the most common mutations are BRAF mutations, which were reported in 40 - 90% of cases from various geographical areas (5–7). BRAF is the main subtype of RAF kinase that may contribute to cell proliferation, growth, division and plays a key role in tumorigenesis (7). The mutation of BRAF V600E could trigger tumorigenesis through constitutively activating the MAPK pathway (8, 9). However, the function of BRAF V600E as a biomarker in driving aggressiveness in PTC continues to be debatable because of the limited large cohort. To date, the relationship between the BRAF V600E mutation in PTC and cervical lymph node metastasis (LNM), remains disputable. The majority of studies claim that the BRAF V600E mutation was associated with poor clinicopathologic outcomes in patients with PTC, including neck nodal metastasis (8, 10, 11). By contrast, some reports suggest that the BRAF V600E variant had no significant association with neck nodal metastasis (7, 12, 13). Therefore, it is still controversial whether the BRAF V600E mutation is associated with cervical LNM. We suspect that this may be due to some selection bias in the tumors included in previous studies, such as large tumor size, multifocality, and bilateral tumors.

In this study, we retrospectively analyzed the clinical, molecular and ultrasonic characteristics in PTC with BARF V600E mutation to find out the influencing factors of cervical LNM.

PATIENTS AND METHODS

Study Population and Design

The clinical records of 487 patients who underwent genotyping for 77 PTC-associated variants and partial or total thyroidecomy in Sir Run Run Shaw Hospital from January 2018 to October 2021 were collected. We obtained written informed consents for all patients, their relatives for FNA, and the collection of DNA samples from FNA or surgery for next generation sequencing. All the procedures described in this study were in accordance with institutional ethical standards. We included patients according to the following criteria: ① age ≥18 years old for all 487 patients. A total of 195 patients were without BRAF V600E mutation, ② lack of complete clinical, molecular, or imaging data, ③ a history of previous thyroid surgery, ④ other extra-thyroid malignancies, and ⑤ age <18 years old. Finally, 292 patients were enrolled in this research.

In this study, the patient’s age, sex, size of the tumor (maximum diameter in US), LNM (central or lateral cervical) in pathology, LNM in US, occurrence of capsular invasion, presence of Hashimoto’s thyroiditis (HT), fociality (unifocal or multifocal), lobe of tumor (left or right), combination of BRAF V600E and other gene variants, ultrasonic features of tumor (location, margin, shape, internal content, echogenicity, calcification) were analyzed. We selected unifocal tumors for ultrasonic characteristic analysis.

Ultrasonic Characteristic Analysis

US examination was performed by sonographers specializing in head and neck imaging, especially in thyroid, who have 10–20 years of experience. The sonographers who performed the US examination prospectively recorded the US imaging features of the thyroid tumors and central or lateral cervical lymph node status. The ultrasonic image information of thyroid tumors we collected included size, location, composition, margin, shape, echogenicity, and echogenic foci. Lymph nodes with suspicious metastasis by US had the following characteristics: cystic aspect, microcalcification, peripheral vascularity, hyperechogenicity, round shape, and loss of hilum (14). If more than one nodule with suspicion of malignancy was found in thyroid gland, the maximum diameter of lesions was recorded and included in the data analysis.

Molecular Analysis

DNA mutation analysis was performed using customized next generation sequencing on an Illumina (San Diego, CA, USA) MiSeq targeting 77 genes (including BRAF, RAS, TP53, TERT, NOTCH1, TSHR, ATM, APC, CDC6/RET, etc.) at the Molecular Pathology Diagnostic Center in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. All identified mutations were validated by Sanger sequencing and matched-normal gDNA. All samples were obtained from FNA or surgical specimens. We considered the tumor as mutated for a particular gene if, at least, one of the samples harbored a mutation when multiple samples from different areas were tested.

Statistical Analysis

Data were analyzed using SPSS 25.0 software (IBM). Measurement data were presented as mean ± SD. or median and range. Categorical data were summarized with frequencies and percentages. Pearson c² test and Fisher’s exact test were used to calculate the bivariate analysis of the relationship between LNM and clinical, molecular, or ultrasonic features in PTCs with the BRAF V600E mutation. A multivariate analysis was performed using binary logistic regression analysis for variables, which were significant in the bivariate analysis. The
odds ratio (OR) value and 95% CI were reported. P values less than 0.05 were considered statistically significant.

RESULTS

Patient Characteristics

In our study, 292 patients diagnosed with the BRAF V600E mutation related PTC were included. The average age (± SD) was 45.6 ± 11.8 years (range, 23–77 years), and 77.4% of the patients were female (226 women and 66 men). In all PTCs, cervical LNM (100 central, 4 lateral cervical, 43 central, and lateral cervical) occurred in 50.3% of patients. A total of 175 patients with single-focal tumors were included for the ultrasonic characteristic analysis. Tables 1–3 show the clinical, ultrasonic, and molecular factors of the patients.

Association of LNM and Clinical, Molecular, and Ultrasonic Characteristics of PTCs with BRAF V600E Mutation

In the univariate analysis of clinical and molecular features in all PTCs with BRAF V600E mutation (Table 1), the LNM was found to be significantly associated with age (P = 0.010), size (P = 0.000), lobe (P = 0.000), focality (P = 0.003), LNM on US (P = 0.000), and capsular invasion (P = 0.010). However, no significant association was found between LNM and other clinical characteristics, such as sex (P = 0.106), HT (P = 0.199), and combination of BRAF V600E with other variants (P = 0.063).

In ultrasonic image characteristics of all unifocal PTCs with BRAF V600E mutation (Table 2), location (P = 0.484), internal content (P = 0.837), and echogenicity (P = 0.101) were not statistically significant variables associated with LNM. However, margin (P = 0.036), shape (P = 0.046), and microcalcification (P = 0.002) were significantly associated with LNM.

The combination of BRAF V600E with other mutations is shown in Table 3. A total of 18 other gene mutations and fusions were identified, including mutations carried by other thyroid tumors from the same patient, in addition to the BRAF V600E mutated PTC. The frequency of LNM was 100.0% in patients with TERT promoter and PTEN mutation and 71.4% in patients with TP53 mutation.

Multivariate Logistic Regression Analysis

In multivariate analysis, LNM in PTCs with BRAF V600E mutation was significantly associated with age ≤ 45 years (OR = 1.869, P = 0.020, 95% CI = 1.106 - 3.158), size ≥ 1cm (OR = 3.131, P = 0.001, 95% CI = 1.578 - 6.212), LNM on US (OR = 6.962, P = 0.000, 95% CI = 2.611 – 20.318).

| Variables | - | + | X² | P value |
|-----------|---|---|----|---------|
| Sex       |   |   |    |         |
| Female    | 118 (52.2) | 108 (47.8) | 2.611 | 0.106 |
| Male      | 27 (40.9) | 39 (59.1) |       |        |
| Age (years) |     |     |    |         |
| ≤45       | 64 (42.4) | 87 (57.6) | 6.618 | 0.010 |
| >45       | 81 (57.4) | 60 (42.6) |       |        |
| Size (cm) |     |     |    |         |
| <1        | 129 (58.1) | 93 (41.9) | 26.454 | 0.000 |
| ≥1        | 16 (22.9) | 54 (77.1) |       |        |
| Focality  |     |     |    |         |
| Unifocal  | 100 (57.1) | 75 (42.9) | 9.789 | 0.002 |
| Multifocal| 45 (58.5) | 72 (41.5) |       |        |
| Lobe      |     |     |    |         |
| Left      | 58 (56.3) | 45 (43.7) | 17.094 | 0.000 |
| Right     | 69 (56.1) | 54 (43.9) |       |        |
| Bilaterality| 18 (27.3) | 48 (72.7) |        |        |
| LNM in US |     |     |    |         |
| +         | 7 (12.1) | 51 (87.9) | 40.906 | 0.000 |
| =         | 138 (59.0) | 96 (41.0) |       |        |
| Capsular invasion | | | | |
| +         | 7 (25.9) | 20 (74.1) | 6.702 | 0.010 |
| -         | 138 (52.1) | 127 (47.9) |       |        |
| HT        |     |     |    |         |
| +         | 41 (56.2) | 32 (43.8) | 1.648 | 0.199 |
| -         | 104 (47.5) | 115 (52.5) |       |        |
| Other variants |   |   |    |         |
| +         | 45 (42.5) | 61 (57.5) | 3.455 | 0.063 |
| -         | 100 (53.8) | 86 (46.2) |       |        |

LNM, lymph node metastasis; PTC, papillary thyroid cancer; US, ultrasound; HT, Hashimoto’s thyroiditis; a, pairwise comparisons were not statistically significant; b, pairwise comparisons were statistically significant (P < 0.05).
TABLE 2 | Association between LNM and US characteristics of PTCs with the BRAF V600E mutation.

| Variables        | LNM (%) | X²  | P value |
|------------------|---------|-----|---------|
|                  | -       | +   |         |
| Location         |         |     |         |
| Upper third      | 30 (53.6) | 26 (46.4) | 2.450 | 0.484 |
| Middle third     | 22 (56.4) | 17 (43.6) |     |       |
| Lower third      | 46 (62.2) | 28 (37.8) |     |       |
| Isthmus          | 2 (33.3) | 4 (66.7) |     |       |
| Margin           |         |     |         |
| Smooth           | 56 (65.1) | 30 (34.9) | 4.390 | 0.036 |
| Ill-defined      | 44 (49.4) | 45 (50.6) |     |       |
| Shape            |         |     |         |
| Oval             | 27 (46.6) | 31 (53.4) | 3.974 | 0.046 |
| Tailor-than-wide | 73 (62.4) | 44 (37.6) |     |       |
| Internal content |         |     |         |
| Solid            | 99 (57.2) | 74 (42.8) | 0.042 | 0.837 |
| Cystic and solid | 1 (50.0) | 1 (50.0) |     |       |
| Echogenicity     |         |     |         |
| Hypoechochogenicity | 100 (57.8) | 73 (42.2) | 2.697 | 0.101 |
| Iso/Hyperechochogenicity | 0 (0.0) | 2 (100.0) |     |       |
| Microcalcification |         |     |         |
| +                | 47 (47.0) | 53 (53.0) | 9.802 | 0.002 |
| –                | 53 (70.7) | 22 (29.3) |     |       |

LNM, lymph node metastasis; PTC, papillary thyroid cancer; US, ultrasound; microcalcification, calcification < 0.2 cm in diameter.

= 2.924 - 16.572), bilaterality (OR = 1.626, P = 0.007, 95% CI = 1.142 - 2.314), ill-defined margins (OR = 1.980, P = 0.033, 95% CI = 1.057 - 3.709), and microcalcification (OR = 2.786, P = 0.002, 95% CI = 1.464 - 5.303), as shown in Table 4.

DISCUSSION

As one of the most common molecular markers, the BRAF V600E mutation has received wide attention. Many studies have considered that BRAF V600E mutation as independently related to known prognostic factors such as LNM (8, 10, 11). However, some studies take the opposite view (7, 12, 13). This study sought to find the influence factors associated with LNM in PTC with the BRAF V600E mutation and clarify the probable reasons for the disagreement over whether BRAF V600E mutation is associated with LNM. Celik et al. (15) suggested that this difference among the previous studies might be due to different treatment protocols used in different institutions, since LNM is highly detectable when prophylactic lymph node dissection is performed. Whereas, we hypothesized that this difference might be related to selection bias caused by some factors. In this study, we conducted univariate and multivariate logistic regression analyses of the clinical, molecular, and ultrasonic characteristics of PTCs with the BRAF V600E mutation to identify the relevant influencing factors.

Frequency of LNM in PTCs with the BRAF V600E mutation were reported to range from 48–70% from different institutions (7, 12, 15–18). In our research, the incidence of LNM was 50.3%. This is consistent with previous reports. Based on univariate analysis of 292 patients (Table 1), sex and HT coexisting with other variants, showed no significant association with LNM in BRAF-related PTCs. In patients with BRAF V600E mutated PTC, LNM was less frequent in subjects with HT than those without HT (43.8% vs. 52.5%), but there was no statistically significant difference. This is similar to the results of Marotta’s report (19). Other research (20) showed that HT was related to less lymph node metastasis and extrathyroidal extension in PTCs.

TABLE 3 | LNM in PTC patients with combined mutations in BRAF V600E and other genes.

| Other variants | Total | LNM (%) | Other variants | Total | LNM (%) |
|----------------|-------|---------|----------------|-------|---------|
| NOTCH1         | 20    | 12 (60.0) | IDH1           | 6     | 2 (33.3) |
| RET            | 16    | 10 (62.5) | AXIN1          | 5     | 3 (60.0) |
| RAS            | 13    | 7 (53.8) | TSC2           | 5     | 3 (60.0) |
| KMT2C          | 12    | 5 (41.7) | TERT           | 4     | 4 (100.0) |
| ZFHX3          | 12    | 8 (66.7) | TSHR           | 4     | 1 (25.0) |
| NCOA2          | 10    | 4 (40.0) | SPOP           | 4     | 1 (25.0) |
| TPS3           | 7     | 5 (71.4) | CCDC68/RET     | 4     | 2 (50.0) |
| APC            | 3     | 0 (0.0) | DICER1         | 2     | 0 (0.0) |
| ETV6/NTRK3     | 2     | 2 (100.0) | PTEN           | 2     | 2 (100.0) |

LNM, lymph node metastasis; PTC, papillary thyroid cancer.
with the BRAF V600E mutation and may play a protective factor in PTCs by directly or indirectly inhibiting the expression of the BRAF V600E mutation and reducing the presence of the aggressive factors in PTCs with BRAF V600E mutation. Further experiments are needed to clarify whether there is a connection between BRAF V600E and HT in the occurrence and progression of thyroid cancer. In molecular terms, we did not find a significant association between LNM and combined mutations. As shown in Table 3, the frequency of LNM in PTCs with concomitant BRAF and TERT promoter mutations was up to 100%. Several studies have supported that the TERT promoter mutated PTC has poor prognosis and clinical staging and the synergistic effects of concomitant BRAF and TERT promoter mutations may exist (9, 21, 22). The rate of LNM was 71.4% in patients with coexistent mutations of BRAF V600E and TERT. This confirms the previous view that TP53 mutations convey significant adverse prognosis and are associated with tumor progression (23, 24).

In addition, 2 patients with combined PTEN mutation both showed cervical LNM in our research, which may mean that the PTEN variant is also associated with tumor growth, aggressiveness, and poor prognosis (25, 26).

In univariate analysis, LNM were significantly associated with age (≤ 45 years), size (> 1 cm), multifocality, LNM on US, capsular invasion, ultrasonic image features (margin, shape, microcalcification) in BRAF mutated PTCs. Multifocality, capsular invasion, shape showed insignificant after multivariate adjustment. In the multivariate logistic analysis, our results indicated that patients >45 years old had less frequent LNM. Mao’s report (27) defined several significant risk factors of cervical LNM in PTC patients: age (<45 years), gender (male), multifocality, tumor size (>1 cm), tumor location (1/3 upper), capsular invasion by the systematic review, and meta-analysis and showed bilateral tumors were unrelated to LNM in patients with PTC, regardless of the BRAF V600E mutation. The BRAF V600E mutation, gender, multifocality, tumor location, and capsular invasion had no significance for LNM but bilateral tumors are associated with LNM in BRAF V600E-related PTCs. Consistent with our findings, Shi’s result (28) shows that incidence of LNM in PTC patients was significantly higher when the tumor diameter was >1cm, while when the tumor diameter was ≤ 1cm, the BRAF V600E mutation status had no effect on LNM. With regard to the conventional US features, Xu et al. (29) reported that solid component, marked hypoechoicity or hypoechogenicity, microcalcification, ill-defined margins, and taller than wide shape were all not significant in positive BRAF V600E mutation patients with central LNM or lateral LNM. On the contrary, in the present study, US features including ill-defined margins and microcalcification were associated with LNM in positive BRAF V600E mutation PTCs. Some important US predictors might be under debate in certain circumstances. This may be due to the selection bias that occurred in this retrospective unicentric research with limited number of cases. Therefore, further research needs to be performed from multiple centers with a large sample of patients in the future.

CONCLUSION

This study revealed that several significant risk factors for LNM in PTCs with BRAF V600E mutation included: age ≤ 45 years, size ≥ 1 cm, LNM in US, bilaterality, ill-defined margins in US, microcalcification in US.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

YH was responsible for conceptualization, study design, data collection and analysis, writing of the manuscript. LH and YH

Table 4: Multivariate logistic regression analyses: association between LNM and clinical/ultrasonic characteristics of PTCs with the BRAF V600E mutation.

| Characteristics          | OR       | P value | 95% CI for OR |
|--------------------------|----------|---------|---------------|
|                          | Lower    | Upper   |               |
| Age ≤ 45 years           | 1.869    | 0.020   | 1.106 3.158   |
| Size ≥ 1 cm              | 3.121    | 0.001   | 1.578 6.212   |
| LNM in US                | 6.962    | 0.000   | 2.924 16.572  |
| Bilaterality             | 1.626    | 0.007   | 1.142 2.314   |
| Ill-defined margin       | 1.980    | 0.033   | 1.057 3.709   |
| Microcalcification        | 2.786    | 0.002   | 1.464 5.303   |

LNM, lymph node metastasis; PTC, papillary thyroid cancer; US, ultrasound; microcalcification, calcification < 0.2 cm in diameter.
have contributed equally to this work. BZ and LG contributed to study design, writing-reviewing. SL contributed to conceptualization, study design, funding acquisition, writing-reviewing and editing. All authors approved the final version of the manuscript.

FUNDING
This work was supported by the Natural Science Foundation of Zhejiang Province (LY20H180005).

REFERENCES
1. Chen P, Pan L, Huang W, Feng H, Ouyang W, Wu J, et al. BRAF V600E and Lymph Node Metastases in Papillary Thyroid Cancer. Endocr Connect (2020) 9:999–1008. doi: 10.1530/EC-20-0420
2. Rahbari R, Zhang J, Kebebew E. Thyroid Cancer Gender Disparity. Future Oncol (2010) 6:1771–9. doi: 10.2217/fon.10.127
3. Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 375:1054–67. doi: 10.1056/NEJMra1510199
4. Nikiforov YE, Nikiforova MN. Molecular Genetics and Diagnosis of Thyroid Cancer. Nat Rev Endocrinol (2011) 7:569–80. doi: 10.1038/nrendo.2011.142
5. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF Mutations in Thyroid Tumors are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising From Papillary Carcinomas. J Clin Endocrinol Metab (2003) 88:5399–404. doi: 10.1210/jc.2003-030838
6. Seo JY, Choi JR, Moon HJ, Kim E-K, Han KH, Kim H, et al. Clinical Implication of Highly Sensitive Detection of the BRAF(V600E) Mutation in Fine-Needle Aspirations According to the Thyroid Bethesda System in Patients With Conventional Papillary Thyroid Carcinoma. Ann Otol Rhinol Laryngol (2015) 124:392–9. doi: 10.1177/000348941560433
7. Yan C, Huang M, Li X, Wang T, Ling R. Relationship Between BRAF V600E and Clinical Features in Papillary Thyroid Carcinoma. Endocr Connect (2019) 8:988–96. doi: 10.1530/EC-19-0246
8. Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem (2016) 38:763–76. doi: 10.1159/000443032
9. Chung JH. BRAF and TERT Promoter Mutations: Clinical Application in Thyroid Cancer. Endocr J (2020) 67:577–84. doi: 10.1507/endocrj.EJ20-0063
10. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF (V600E) Mutation and the Biology of Papillary Thyroid Cancer. Endocr Relat Cancer (2008) 15:191–205. doi: 10.1677/ERC-07-0212
11. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF V600E Mutation is Associated With Tumor Aggressiveness in Papillary Thyroid Cancer. Cancer Med (2017) 6:1383–9. doi: 10.1002/cam4.1383
12. Lu J, Gao J, Zhang J, Sun J, Wu H, Shi X, et al. Association Between BRAF V600E Mutation and Regional Lymph Node Metastasis in Papillary Thyroid Carcinoma. Int J Clin Exp Pathol (2015) 8:793–9.
13. Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, et al. Investigation of BRAF V600E Detection Approaches in Papillary Thyroid Carcinoma. Pathol Res Pract (2018) 214:303–7. doi: 10.1016/j.prp.2017.09.011
14. Leenhart L, Erdogan MF, Hegenus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients With Thyroid Cancer. Eur Thyroid J (2013) 2:147–59. doi: 10.1159/000354537
15. Celik M, Bulbul BY, Ayurtuk S, Durmus Y, Gurkan H, Can N, et al. The Relation Between BRAF(V600E) Mutation and Clinicopathological Characteristics of Papillary Thyroid Cancer. Med Glas (Zenica) (2020) 17:30–4. doi: 10.17392/1086-20
16. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E Mutation and its Association with Clinico-pathological Features of Papillary Thyroid Cancer: A Meta-Analysis. J Clin Endocrinol Metab (2012) 97:4559–70. doi: 10.1210/jc.2012-2104
17. Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, et al. Allele Percentage of the BRAF V600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression. J Clin Endocrinol Metab (2013) 98:E934–42. doi: 10.1210/jc.2012-3930
18. Dong SY, Chan J, Xia EJ, Lin RX, Du HY, Wang OC, et al. Clinical Analysis of BRAF(V600E) Mutation and Its Correlation With Sonographic Image Characteristics in Papillary Thyroid Carcinoma in Chinese Coastal Areas. Am Surg (2020) 86:450–7. doi: 10.1177/0003134820919734
19. Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, Faggiano A, et al. BRAF Mutation Positive Papillary Thyroid Carcinoma is Less Advanced When Hashimoto’s Thyroiditis Lymphocytic Infiltration is Present. Clin Endocrinol (Oxf) (2013) 79:733–8. doi: 10.1111/cen.12194
20. Zeng R, Jin L, Chen E, Dong S, Cai Y, Huang G, et al. Potential Relationship Between Hashimoto’s Thyroiditis and BRAF(V600E) Mutation Status in Papillary Thyroid Cancer. Head Neck (2016) 38:E1019–25. doi: 10.1002/hed.24149
21. Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of Coexistence of BRAF(V600E) and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid (2017) 27:651–60. doi: 10.1089/thy.2016.0350
22. Trybek T, Walczyk A, Gasior-Perczak D, Pazhaya I, Mikina E, Kowalk A, et al. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. Endocrinology (2019) 160:2328–38. doi: 10.1210/en.2019-00315
23. Poller DN, Glaysher S. Molecular Pathology and Thyroid FNA. Cytopathology (2017) 28:475–81. doi: 10.1111/cyt.12492
24. Haroom Al Rasheed MR, Xu B. Molecular Alterations in Thyroid Carcinoma. Surg Pathol Clin (2019) 12:921–30. doi: 10.1016/j.spc.2019.08.002
25. Duman BR, Kara OI, Uğuz A, Ates BT. Evaluation of PTEN, PI3K, MTO1, and KRAS Expression and Their Clinical and Prognostic Relevance to Differentiated Thyroid Carcinoma. Contemp Oncol (Poland) (2014) 18:324–40. doi: 10.5114/co.2014.43803
26. Sansal I, Sellers WR. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. J Clin Oncol (2004) 22:2954–63. doi: 10.1200/JCO.2004.02.141
27. Mao J, Zhang Q, Zhang H, Zheng K, Wang R, Wang G. Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) (2020) 11:265. doi: 10.3389/fendo.2020.00265
28. Shi CL, Sun Y, Ding C, Lv YC, Qin HD. Correlation Between the BRAF V600E Mutation Status and the Clinicopathologic Features of Papillary Thyroid Carcinoma. Genet Mol Res (2015) 14:7377–85. doi: 10.4238/2015.July.3.13
29. Xu JM, Chen YJ, Dang YY, Chen M. Association Between Preoperative US, Elastography Features and Prognostic Factors of Papillary Thyroid Cancer.

ACKNOWLEDGMENTS
We thank Drs. Yaoyao Shi, Qing Ruan for their help in molecular analysis.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.884428/full#supplementary-material
With BRAFV600E Mutation. *Front Endocrinol (Lausanne)* (2020) 10:902. doi: 10.3389/fendo.2019.00902

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Han, Hou, Zhao, Gao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.